Lamivudine-13C, d2

Lamivudine-13C, d2 is the deuterium labeled and 13C-labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI) . Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].

Product Specifications

CAS Number

[2714473-70-6]

UNSPSC

12352005

Target

HBV

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Smiles

NC1=N[13C](N([C@@H]2CS[C@H](C(O)([2H])[2H])O2)C=C1)=O

Molecular Formula

C7 13CH9D2N3O3S

Molecular Weight

232.26

References & Citations

[1]Colledge D, et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997 Jul;26 (1) :216-25. |[2]Olaniyan LW, et al. Lamivudine-Induced Liver Injury. Open Access Maced J Med Sci. 2015 Dec 15;3 (4) :545-50.